Top

Published in:

01-11-2018 | Original Paper

Cost–Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program

Authors: Catherine Maulsby, Kriti M. Jain, Brian W. Weir, Blessing Enobun, Melissa Werner, Morey Riordan, David R. Holtgrave, A2C Intervention Team

Published in: AIDS and Behavior | Issue 11/2018

Abstract

Linkage to HIV medical care and on-going engagement in HIV medical care are vital for ending the HIV epidemic. However, little is known about the cost–utility of HIV linkage, re-engagement and retention (LRC) in care programs. This paper presents the cost–utility analysis of Access to Care, a national HIV LRC program. Using standard methods from the US Panel on Cost-Effectiveness in Health and Medicine, we calculated the cost–utility ratio. Seven Access to Care programs were cost-effective and two were cost-saving. This study adds to a small but growing body of evidence to support the cost-effectiveness of LRC programs.

Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71. https://doi.org/10.1093/cid/cit420.CrossRef

White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States. Washington, DC: The White House; 2010. http://www.whitehouse.gov/administration/eop/onap/nhas. Accessed 27 Feb 2016.

White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: updated to 2020. Washington, DC: The White House; 2015. https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf. Accessed 27 Feb 2016.

Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800. https://doi.org/10.1093/cid/ciq243.CrossRefPubMedPubMedCentral

Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44. https://doi.org/10.1001/jamainternmed.2013.6841.CrossRefPubMed

Higa DH, Crepaz N, Mullins MM, Prevention Research Synthesis Project. Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996–2014. AIDS Behav. 2016;20(5):951–66. https://doi.org/10.1007/s10461-015-1204-x.CrossRef

Liau A, Crepaz N, Lyles CM, Higa DH, Mullins MM, DeLuca J, et al. Interventions to promote linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative systematic review, 1996–2011. AIDS Behav. 2013;17(6):1941–62. https://doi.org/10.1007/s10461-013-0435-y.CrossRefPubMedPubMedCentral

Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105. https://doi.org/10.1097/qai.0b013e31825bd862.CrossRefPubMed

Nosyk B, Min JE, Lima VD, Hogg RS, Montaner JS, Group SHAs. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. Lancet HIV. 2015;2(9):e393–400. https://doi.org/10.1016/s2352-3018(15)00127-7.CrossRefPubMedPubMedCentral

10.

Shah M, Risher K, Berry SA, Dowdy DW. The epidemiologic and economic impact of improving HIV testing, linkage, and retention in care in the United States. Clin Infect Dis. 2016;62(2):220–9. https://doi.org/10.1093/cid/civ801.CrossRefPubMed

11.

Zhang L, Phanuphak N, Henderson K, Nonenoy S, Srikaew S, Shattock AJ, et al. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study. Lancet HIV. 2015;2(5):e200–7. https://doi.org/10.1016/s2352-3018(15)00020-x.CrossRefPubMed

12.

Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS ONE. 2012;7(12):e51993. https://doi.org/10.1371/journal.pone.0051993.CrossRefPubMedPubMedCentral

13.

Kim JJ, Maulsby C, Zulliger R, Jain K, Charles V, et al., Positive Charge Intervention Team. Cost and threshold analysis of positive charge, a multi-site linkage to HIV care program in the United States. AIDS Behav. 2015;19(10):1735–41. https://doi.org/10.1007/s10461-015-1124-9.CrossRef

14.

Jain KM, Zulliger R, Maulsby C, Kim JJ, Charles V, et al., PCI Team. Cost–utility analysis of three U.S. HIV linkage and re-engagement in care programs from positive charge. AIDS Behav. 2016;20(5):973–6. https://doi.org/10.1007/s10461-015-1243-3.CrossRef

15.

Spaulding AC, Pinkerton SD, Superak H, Cunningham MJ, Resch S, Jordan AO, et al. Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention. AIDS Behav. 2013;17(Suppl 2):S220–6. https://doi.org/10.1007/s10461-012-0353-4.CrossRefPubMed

16.

Renaud A, Basenya O, de Borman N, Greindl I, Meyer-Rath G. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009;21(11):1388–94. https://doi.org/10.1080/09540120902884042.CrossRefPubMed

17.

Jain KM, Maulsby C, Brantley M, Kim JJ, Zulliger R, et al., Team SIFi. Cost and cost threshold analyses for 12 innovative US HIV linkage and retention in care programs. AIDS Care 2016;28(9):1199–204. https://doi.org/10.1080/09540121.2016.1164294.CrossRef

18.

Health Resources and Services Administration. HIV/AIDS Bureau performance measures. http://hab.hrsa.gov/deliverhivaidscare/coremeasures.pdf. Accessed 10 Oct 2017.

19.

Horberg MA, Aberg JA, Cheever LW, Renner P, O’Brien Kaleba E, Asch SM. Development of national and multiagency HIV care quality measures. Clin Infect Dis. 2010;51(6):732–8. https://doi.org/10.1086/655893 (Epub 19 Aug 2010).CrossRef

20.

Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093–103. https://doi.org/10.1001/jama.2016.12195.CrossRef

21.

Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–8.CrossRef

22.

Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96. https://doi.org/10.1001/jamainternmed.2014.8180.CrossRefPubMed

23.

Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. AIDS Behav. 2013;17(5):1632–6. https://doi.org/10.1007/s10461-013-0426-z.CrossRefPubMed

24.

Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB, Sansom SL. Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013;64(2):e15–8. https://doi.org/10.1097/qai.0b013e3182a5c8d4.CrossRefPubMed

25.

Holtgrave DR, Hall HI, Wehrmeyer L, Maulsby C. Costs, consequences and feasibility of strategies for achieving the goals of the national HIV/AIDS strategy in the United States: a closing window for success? AIDS Behav. 2012;16(6):1365–72. https://doi.org/10.1007/s10461-012-0207-0.CrossRefPubMed

26.

World Health Organization. Choosing interventions that are cost-effective: 2014. http://www.who.int/choice/en/. Accessed 10 Oct 2017.

27.

Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141–5. https://doi.org/10.1093/heapol/czw096.CrossRefPubMed

28.

World Bank. GDP per capita (current US$) 2013. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.

29.

Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–41. https://doi.org/10.1001/archinte.163.14.1637.CrossRefPubMed

30.

Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med. 1997;127(11):955–65.CrossRef

31.

Walensky RP. Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. Top HIV Med. 2009;17(4):130–4.PubMed

32.

Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22(5):417–30.CrossRef

Title: Cost–Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program
Authors: Catherine Maulsby
Kriti M. Jain
Brian W. Weir
Blessing Enobun
Melissa Werner
Morey Riordan
David R. Holtgrave
A2C Intervention Team
Publication date: 01-11-2018
Publisher: Springer US
Published in: AIDS and Behavior / Issue 11/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-017-2015-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cost–Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2018

Missed Opportunities for HIV Prevention: Individuals Who HIV Seroconverted Despite Accessing Healthcare

Traumatic Events and HIV Sexual Risk Behaviors Among Migrant and Non-Migrant Male Market Workers in Central Asia

Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men

Sexual Sensation Seeking: A Validated Scale for Spanish Gay, Lesbian and Bisexual People

An Information–Motivation–Behavioral Skills Model of PrEP Uptake

Motivated Reasoning and HIV Risk? Views on Relationships, Trust, and Risk from Young Women in Cape Town, South Africa, and Implications for Oral PrEP

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page